Friday, 22 Jun 2018

You are here

Laparoscopic Gastric Sleeve Compared to Bypass Bariatric Surgery

JAMA reports the results of a 5 year Finnish study comparing the results of laparoscopic sleeve gastrectomy vs Roux-en-Y gastric bypass and shows that gastric bypass yielded greater weight loss at 5 years, the difference was not statistically significant, in patients with morbid obesity. 

The Sleeve vs Bypass (SLEEVEPASS) study included 240 adults with morbid obesity received open-label randomized intervention iwth either sleeve gastrectomy or gastric bypass with a 5-year follow-up period. The primary end point was weight loss evaluated by percentage excess weight loss. The pPrespecified equivalence margins were −9% to +9% excess weight loss.

The patients had a mean baseline BMI of 45.9, and 42.1% had type 2 diabetes, 34.6% dyslipidemia, and 70.8% hypertension.  The results are shown in the table below:

 SleeveBypass
% Wt. Loss49%57%
DM remission37%45%
D/C Statins47%60%
D/C BP meds29%51%
Morbidity rate19%26%

 

 

 

 

 

 

 

 

While gastric bypass results were generally superior to gastric sleeve results, these were not significantly different. 

These results are similar to that seen in the STAMPEDE study showing similar (nonsignificant) but better results for bypass compared to gastric sleeve in the control of type II diabetes. (citation source: https://buff.ly/2rdYC3M

The five-year follow-up of this original study showed that:

  • 88% of gastric bypass and sleeve gastrectomy patients maintained healthy blood glucose levels without needinginsulin.
  • 29% of gastric bypass patients and 23% of sleeve gastrectomy patients achieved normal blood glucose levels
  • Weight loss was significantly greater with gastric bypass and sleeve gastrectomy compared than with medications 

The effects of both surgical procedures to normalize glucose levels did, however, diminish over time, and some late complications were noted with surgery.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

EULAR 2018 - Day 3 Report

Day 3 highlights include Behcet’s responds to apremilast and that biologics do not differentially affect TKR/THR post-operative infection rates. Be sure to check out today's podcast as well. 

Canada Closer to Marijuana Approval

Reuters reports that Canada’s Senate on Thursday voted to legalize recreational marijuana, clearing a major hurdle that puts the country on track to become the first Group of Seven nation to permit national use of the drug.

Now the law and amendments go to the House of Commons who will need to decide on before the law can be passed.

Advance Practice Clinicians Proliferating in Specialty Practices

An analysis of SK&A outpatient provider files, covering 90% of physician practices in the United States, shows that between 2008 to 2016, there was a 22% increase in the employment of advanced practice clinicians (APCs) by specialty practices.  By 2016, 28% of all specialty practices employed APCs.

Trump Blasts Drug Makers on the Price of Drugs

Reuter's reports Friday that President Donald Trump blasted drugmakers and healthcare “middlemen” for making prescription drugs unaffordable for Americans. Nonetheless, many healthcare stocks rose as it became clear the administration had avoided taking aggressive and direct measures to cut drug prices.

Here are many New Sources on this developing story:

Patients May Not Fill Your Prescription

A new study linking administrative claims and electronic health records (EHRs) shows that nearly 40% of patients fill and take newly prescribed methotrexate (MTX), tofacitinib or biologics. 

Kan et al set out to estimate the extent and predictors of primary nonadherence in rheumatoid arthritis (RA) patients who received new prescriptions for methotrexate, biologics or tofacitinib.